## 一句话总结
“少配了一瓶试剂”背后,一瓶没被扔掉的旧缓冲液、一个被骂"钓鱼"的样本库、首版失败后补做的第八个版本,共同拼出了抗癌药赫赛汀近二十年的来路。
## 核心要点
1. 1979年Hunter因一瓶旧缓冲液意外发现酪氨酸磷酸化,新配试剂一度重复不出,他查明是老化改变了酸碱度,1980年发表这一基础发现。
2. 1987年Slamon依托肿瘤组织库,在189份乳腺癌样本中发现约3成存在HER2扩增且结局更差,而该受体的胞内段正是酪氨酸激酶。
3. 1992年Carter团队人源化抗体首版"能结合、没功能",再设计7个版本后第8个成功,成为1998年获批的赫赛汀的底子。
## 引用文献
- Transforming gene product of Rous sarcoma virus phosphorylates tyrosine — https://pubmed.ncbi.nlm.nih.gov/6246487/
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene — https://pubmed.ncbi.nlm.nih.gov/3798106/
- Humanization of an anti-p185HER2 antibody for human cancer therapy — https://pubmed.ncbi.nlm.nih.gov/1350088/
- The genesis of tyrosine phosphorylation — https://pubmed.ncbi.nlm.nih.gov/24789824/
- Targeting the function of the HER2 oncogene in human cancer therapeutics — https://pubmed.ncbi.nlm.nih.gov/17486079/
- Where Cures Begin: Tony Hunter — https://www.salk.edu/salk-talk-podcast/episode-002-where-cures-begin-tony-hunter/
- S02:The Culprit Is Cancer — https://newsroom.ucla.edu/magazine/cancer-dennis-slamon-herceptin-her-2
- S03:Herceptin—a targeted antibody therapy for breast cancer — https://laskerfoundation.org/winners/herceptin-a-targeted-antibody-therapy-for-breast-cancer/
- S04:Salk scientist Tony Hunter receives 2026 Albany Prize — https://www.salk.edu/news-release/salk-scientist-tony-hunter-receives-2026-albany-prize/
## 免责声明
本文为科学故事分享,不构成任何医疗建议,具体诊疗请遵医嘱。